AR089324A1 - COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS - Google Patents
COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINSInfo
- Publication number
- AR089324A1 AR089324A1 ARP120104817A ARP120104817A AR089324A1 AR 089324 A1 AR089324 A1 AR 089324A1 AR P120104817 A ARP120104817 A AR P120104817A AR P120104817 A ARP120104817 A AR P120104817A AR 089324 A1 AR089324 A1 AR 089324A1
- Authority
- AR
- Argentina
- Prior art keywords
- recombinant proteins
- kits
- protein
- compositions
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Procedimiento para alterar un patrón de sialilación de una o más proteínas recombinantes expresadas en una célula, en el que la célula está modificada genéticamente para expresar recombinantemente una a2,3-sialiltransferasa para sialilar la proteína. Este sistema de expresión incrementa la sialilación de la proteína que se expresa (FVIII - factor anti-hemofílico (AHF) ó factor de von Willebrand (vWF)), en particular la cantidad de un ácido siálico enlazado por a2,3 unido a la proteína. Composición. Célula. Método de tratamiento.Procedure for altering a sialylation pattern of one or more recombinant proteins expressed in a cell, in which the cell is genetically modified to recombinantly express an a2,3-sialyltransferase to sialylate the protein. This expression system increases the sialylation of the protein that is expressed (FVIII - anti-hemophilic factor (AHF) or von Willebrand factor (vWF)), in particular the amount of a sialic acid bound by a2.3 bound to the protein . Composition. Cell. Treatment method
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161577291P | 2011-12-19 | 2011-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR089324A1 true AR089324A1 (en) | 2014-08-13 |
Family
ID=47681979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120104817A AR089324A1 (en) | 2011-12-19 | 2012-12-19 | COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR089324A1 (en) |
AU (1) | AU2012340501A1 (en) |
UY (1) | UY34527A (en) |
WO (1) | WO2013093760A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3889173T3 (en) * | 2013-02-15 | 2023-10-09 | Bioverativ Therapeutics Inc | OPTIMIZED FACTOR VIII GENE |
US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
EP3042952A1 (en) | 2015-01-07 | 2016-07-13 | CEVEC Pharmaceuticals GmbH | O-glycan sialylated recombinant glycoproteins and cell lines for producing the same |
KR20180006453A (en) | 2015-05-22 | 2018-01-17 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | A cleaved von Willebrand factor polypeptide to treat hemophilia |
DK3298036T3 (en) | 2015-05-22 | 2022-06-07 | CSL Behring Lengnau AG | Methods for preparing modified von Willebrand factor |
MA43270A (en) | 2015-11-19 | 2021-06-02 | Takeda Pharmaceuticals Co | RECOMBINANT HUMAN ESTERASE C1 INHIBITOR AND ITS USES |
SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
JP7217630B2 (en) | 2016-02-01 | 2023-02-03 | バイオベラティブ セラピューティクス インコーポレイテッド | Optimized Factor VIII gene |
JP2020504082A (en) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | Truncated von Willebrand factor polypeptide for extravascular administration in the treatment or prevention of blood clotting disorders |
DK3538133T3 (en) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR THE TREATMENT OF HEMOPHILIA |
EP3382014A1 (en) * | 2017-03-29 | 2018-10-03 | CEVEC Pharmaceuticals GmbH | Recombinant glycoproteins with reduced antennary fucosylation |
BR112019026743A2 (en) | 2017-06-22 | 2020-06-30 | CSL Behring Lengnau AG | modulation of fviii immunogenicity by truncated VWF |
US20220389082A1 (en) | 2019-07-04 | 2022-12-08 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
WO2021081670A1 (en) * | 2019-11-01 | 2021-05-06 | The University Of British Columbia | Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins |
WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US5149637A (en) | 1987-04-06 | 1992-09-22 | Scripps Clinic & Research Foundation | Recombinant Factor VIIIC fragments |
US5043429B1 (en) | 1987-05-01 | 1997-10-14 | Scripps Research Inst | Protein fragments containing factor VIII binding domain of von willebrand factor |
US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
ATE425175T1 (en) | 1996-01-23 | 2009-03-15 | Operon Biotechnologies Inc | METHODS AND COMPOSITIONS FOR DETERMINING SEQUENCES OF NUCLEIC ACID MOLECULES |
US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
AT403765B (en) | 1996-04-12 | 1998-05-25 | Immuno Ag | METHOD FOR PRODUCING A PREPARATION CONTAINING A HIGHLY CLEANED COMPLEX |
US6120460A (en) | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
NZ501774A (en) | 1997-07-22 | 2002-02-01 | Qiagen Genomics Inc | Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
CN100457914C (en) | 1999-04-15 | 2009-02-04 | 荷兰克鲁塞尔公司 | Recombinant protein production in human cell using sequences encoding adenovirus E1 protein |
US20060099685A1 (en) * | 1999-04-15 | 2006-05-11 | Yallop Christopher A | Recombinant expression of factor VIII in human cells |
US6664112B2 (en) | 2000-06-02 | 2003-12-16 | Blue Heron Biotechnology, Inc. | Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides |
WO2003054232A2 (en) | 2001-12-13 | 2003-07-03 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
US7642078B2 (en) | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
TWI488640B (en) * | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | Pharmaceutical preparation |
TWI532495B (en) * | 2009-10-05 | 2016-05-11 | 菲瑞茵國際中心股份有限公司 | Pharmaceutical preparation |
US20110086362A1 (en) | 2009-10-09 | 2011-04-14 | Massachusetts Institute Of Technology | High-Throughput Method for Quantifying Sialylation of Glycoproteins |
-
2012
- 2012-12-17 WO PCT/IB2012/057392 patent/WO2013093760A2/en active Application Filing
- 2012-12-17 AU AU2012340501A patent/AU2012340501A1/en not_active Abandoned
- 2012-12-19 AR ARP120104817A patent/AR089324A1/en not_active Application Discontinuation
- 2012-12-19 UY UY0001034527A patent/UY34527A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2013093760A3 (en) | 2013-11-14 |
UY34527A (en) | 2013-07-31 |
AU2012340501A1 (en) | 2013-07-11 |
WO2013093760A2 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR089324A1 (en) | COMPOSITIONS, METHODS AND KITS FOR THE PREPARATION OF SEALED RECOMBINANT PROTEINS | |
AR124871A2 (en) | MANUFACTURING METHODS FOR THE CONTROL OF THE CONTENT OF C-TERMINAL LYSINE, GALACTOSE AND SIALIC ACID IN RECOMBINANT PROTEINS | |
CL2018000238A1 (en) | Peptide mixture (divisional application 201601405) | |
CY1122800T1 (en) | COMPOSITIONS OF FACTOR VIII AND METHODS OF MAKING AND USING THEM | |
BR112014019901A8 (en) | RECOMBINANT FACTOR VIII PROTEINS | |
CO2018005215A2 (en) | Specific constructions of the liver for expression of factor viii | |
ES2600879T3 (en) | Preparations containing von Willebrand factor (FvW) and related procedures, kits and uses | |
CY1122691T1 (en) | SERUM ALBUMIN-BINDING PROTEINS | |
EA201190326A8 (en) | GROWTH HORMONE POLYPEPTIDES AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
PE20130041A1 (en) | FIBRONECTIN SCAFFOLDING DOMAIN PROTEINS THAT BIND INTERLEUKIN 23 (IL-23) | |
GT201300295A (en) | "COMPOSITIONS CONTAINING, METHODS THAT INVOLVE, AND USES OF DOLASTATIN DERIVATIVES UNITED TO NON-NATURAL AMINO ACIDS" | |
BR112015013311A2 (en) | tolerance induction and factor 8 mutation repair | |
BRPI0609797B8 (en) | improved nanobodies for the treatment of aggregation-mediated disorders | |
IN2014DN09815A (en) | ||
BR122021020829B8 (en) | NON-NATURALLY OCCURRING FACTOR H-BINDING PROTEIN (FHBP), COMPOSITION, AND GENETICALLY MODIFIED NEISSERIA MENINGITIDIS HOST CELL | |
BR112016020584A2 (en) | SELF-ORGANIZABLE PEPTIDE COMPOSITIONS | |
PE20140190A1 (en) | NOTUM PROTEIN MODULATORS AND METHODS OF USE | |
CL2013000475A1 (en) | Relaxin polypeptides comprising one or more unnatural encoded amino acids; isolated nucleic acid; method to prepare the relaxin polypeptide. | |
BR112016011224A2 (en) | LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION | |
EA201592022A1 (en) | Fragmented by thrombinom LINKER, CONTAINING XTEN, AND ITS APPLICATION | |
AR091647A1 (en) | PURIFICATION OF IDURONATE-2-SULFATASE | |
BR112013017367A2 (en) | caracarp polypeptide, nucleic acid sequence, pharmaceutical composition and method for producing at least one carabin polypeptide | |
EA202190244A2 (en) | OVEREXPRESSION OF N-GLYCOSYLATION PATH REGULATORS FOR MODULATION OF GLYCOSYLATION OF RECOMBINANT PROTEINS | |
PE20190966A1 (en) | FACTOR VIII ADDRESSED TO RED BALLOONS AND METHOD FOR USE | |
BR112014008680A2 (en) | transferrin-tumstatin fusion protein and methods for producing and using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |